CA3241878A1 - Novel auristatin analogs and immunoconjugates thereof - Google Patents

Novel auristatin analogs and immunoconjugates thereof

Info

Publication number
CA3241878A1
CA3241878A1 CA3241878A CA3241878A CA3241878A1 CA 3241878 A1 CA3241878 A1 CA 3241878A1 CA 3241878 A CA3241878 A CA 3241878A CA 3241878 A CA3241878 A CA 3241878A CA 3241878 A1 CA3241878 A1 CA 3241878A1
Authority
CA
Canada
Prior art keywords
compound
structural formula
immunoconjugate
antibody
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3241878A
Other languages
English (en)
French (fr)
Inventor
Richard Hui Li
Dong Jun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adcentrx Therapeutics Inc
Original Assignee
Adcentrx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcentrx Therapeutics Inc filed Critical Adcentrx Therapeutics Inc
Publication of CA3241878A1 publication Critical patent/CA3241878A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3241878A 2021-12-23 2022-12-21 Novel auristatin analogs and immunoconjugates thereof Pending CA3241878A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293583P 2021-12-23 2021-12-23
US63/293,583 2021-12-23
PCT/US2022/053738 WO2023122228A1 (en) 2021-12-23 2022-12-21 Novel auristatin analogs and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
CA3241878A1 true CA3241878A1 (en) 2023-06-29

Family

ID=86903604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3241878A Pending CA3241878A1 (en) 2021-12-23 2022-12-21 Novel auristatin analogs and immunoconjugates thereof

Country Status (10)

Country Link
US (1) US20250049937A1 (https=)
EP (1) EP4453000A4 (https=)
JP (1) JP2025500404A (https=)
KR (1) KR20240152826A (https=)
CN (1) CN118829645A (https=)
AU (1) AU2022422015A1 (https=)
CA (1) CA3241878A1 (https=)
IL (1) IL313784A (https=)
TW (1) TW202328162A (https=)
WO (1) WO2023122228A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067221A1 (zh) * 2023-09-26 2025-04-03 上海齐鲁制药研究中心有限公司 奥瑞他汀衍生物及其抗体药物偶联物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
CA2951368A1 (en) * 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
CA3205824A1 (en) * 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CN119241554A (zh) * 2017-12-15 2025-01-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途

Also Published As

Publication number Publication date
IL313784A (en) 2024-08-01
TW202328162A (zh) 2023-07-16
JP2025500404A (ja) 2025-01-09
WO2023122228A1 (en) 2023-06-29
US20250049937A1 (en) 2025-02-13
KR20240152826A (ko) 2024-10-22
CN118829645A (zh) 2024-10-22
EP4453000A4 (en) 2025-12-24
EP4453000A1 (en) 2024-10-30
AU2022422015A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
CA2852860C (en) Cytotoxic peptides and antibody drug conjugates thereof
RS64961B1 (sr) Derivati kamptotecina
CA3080236A1 (en) Bioactive molecule conjugate, preparation method and use thereof
CA3027178A1 (en) Anti-egfr antibody drug conjugates
CA2951368A1 (en) Auristatin derivatives and conjugates thereof
US20260027226A1 (en) Antibody-drug conjugates
WO2024059236A1 (en) Novel camptothecin analogs and immunoconjugates thereof
CA3202759A1 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2025518554A (ja) リガンド薬物複合体及びその使用
CA3241878A1 (en) Novel auristatin analogs and immunoconjugates thereof
CA3236944A1 (en) Novel auristatin analogs and immunoconjugates thereof
WO2025149667A1 (en) Antibody drug conjugates and uses thereof
IL322216A (en) Drug conjugates, methods for their preparation and use
KR20250049520A (ko) 인간 trop2에 대한 항체를 포함하는 항체-약물 접합체 및 이의 용도
HK40117241A (zh) 新型澳瑞他汀类似物及其免疫偶联物
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40115429A (zh) 新型澳瑞他汀类似物及其免疫偶联物
WO2025176733A1 (en) Antibody-drug conjugates involving small molecule atr/chk1 inhibitors
WO2024127333A1 (en) Cytotoxic compounds
WO2024127332A1 (en) Cytotoxic compounds
HK40117773A (zh) 包含抗人trop2的抗体的抗体-药物缀合物及其用途
HK1233252A1 (en) Bifunctional cytotoxic agents

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED

Effective date: 20240704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241112

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251106

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251106